Breaking News

Catalent, Adamas Enter CTM Agreement

By Kristin Brooks | January 8, 2014

Catalent to manufacture ADS-5102 for Phase III trials

Catalent Pharma Solutions and Adamas Pharmaceuticals have entered an agreement for the manufacture of ADS-5102 (amantadine HCl) extended release capsules for Phase III trials. ADS-5102 is an investigational drug being developed for Levodopa-Induced Dyskinesia (LID) in patients with Parkinson’s disease.
“We believe Catalent’s capabilities make them the right choice to support execution of our upcoming clinical trials,” said Gregory T. Went, Ph.D., Adamas chairman and chief executive officer.
Barry Littlejohns, president of Catalent’s Advanced Delivery Technologies business, said, “Our controlled release formulation expertise and drug delivery technologies will ultimately benefit patients with better treatments. We are pleased Adamas selected Catalent for the development and supply of ADS-5102 which, if approved, will be the first medical treatment indicated for patients with LID in Parkinson’s disease.”